EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CSPC Pharmaceutical Group's Enterprise Value is $9,253 Mil.
CSPC Pharmaceutical Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $0 Mil. Therefore, CSPC Pharmaceutical Group's EV-to-FCF for today is .
The historical rank and industry rank for CSPC Pharmaceutical Group's EV-to-FCF or its related term are showing as below:
CSPCY'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 18.76
Current: 18.76
During the past 13 years, the highest EV-to-FCF of CSPC Pharmaceutical Group was 18.76. The lowest was 0.00. And the median was 0.00.
CSPCY's EV-to-FCF is ranked better than 53.94% of 558
companies
in the Drug Manufacturers industry
Industry Median: 20.045
vs CSPCY: 18.76
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CSPC Pharmaceutical Group (OTCPK:CSPCY) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CSPC Pharmaceutical Group's PE Ratio (TTM) for today is calculated as:
CSPC Pharmaceutical Group's share price for today is $3.584.
CSPC Pharmaceutical Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.162.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
CSPC Pharmaceutical Group EV-to-FCF Related Terms
CSPC Pharmaceutical Group EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSPC Pharmaceutical Group EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where CSPC Pharmaceutical Group's EV-to-FCF falls into.
CSPC Pharmaceutical Group's current Enterprise Value is $9,253 Mil.
CSPC Pharmaceutical Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is CSPC Pharmaceutical Group (CSPCY) Overvalued in 2026?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued.
The current stock price of $3.58 is trading 6.4% above its estimated GF Value™ of $3.37.
GuruFocus considers CSPC Pharmaceutical Group to be Fairly Valued.
Key valuation signals for CSPCY:
EV-to-FCF:
GF Value™: $3.37 vs. price of $3.58 (6.4% above fair value)
No single metric tells the full story. See the CSPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
76GF Score
Get the complete analysis for CSPCY
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSPCY has been successfully added to your 
